Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: OpGen Inc

Market Cap 24.36M 21.04M 19.39M 18.15M 34.01M 2.32B 34.53M 229M 89.24M 1.13B 91.41M 89.46M 3.9B P/E Ratio 2024
0.26x
P/E Ratio 2025 6.86x
Enterprise Value 25.67M 22.17M 20.43M 19.13M 35.84M 2.44B 36.4M 241M 94.07M 1.19B 96.35M 94.3M 4.11B EV / Sales 2024
1.29x
EV / Sales 2025 5.39x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 50 2025-11-30
Chief Tech/Sci/R&D Officer 37 2025-03-31
Chief Operating Officer 54 2024-12-03
Director TitleAgeSince
Chairman 36 2024-08-01
Director/Board Member 39 2024-08-08
Director/Board Member 40 2024-08-08
Change 5-day change 1-year change 3-year change Capi.($)
+21.45%+1,817.73% - - 6.39M
-0.35%+0.97%-15.96%-12.73% 42.96B
+3.27%+3.22%+274.68%+508.57% 31.73B
-0.05%-1.53%+13.52%-14.75% 30.22B
+1.75%-1.98%-4.26%+24.18% 28.94B
+4.09%-1.98%+11.99%+17.37% 23.87B
-1.29%+3.57%+54.76%+115.80% 13.57B
-0.40%-1.29%+6.06%+7.59% 12.96B
+2.61%+4.95% - - 13.39B
-0.82%-1.60%+105.74%+76.04% 12.2B
Average +3.01%-0.71%+55.82%+90.26% 23.31B
Weighted average by Cap. +1.09%-1.08%+54.53%+95.98%

Financials

2024 2025
Net sales 5.2M 4.49M 4.14M 3.87M 7.25M 494M 7.37M 48.83M 19.04M 240M 19.5M 19.09M 832M 30.2M 26.08M 24.04M 22.5M 42.16M 2.87B 42.82M 284M 111M 1.4B 113M 111M 4.84B
Net income 11.99M 10.36M 9.55M 8.93M 16.74M 1.14B 17M 113M 43.94M 555M 45.01M 44.05M 1.92B 23.62M 20.4M 18.8M 17.6M 32.98M 2.25B 33.49M 222M 86.55M 1.09B 88.65M 86.76M 3.78B
Net Debt 711K 614K 566K 530K 993K 67.58M 1.01M 6.68M 2.61M 32.89M 2.67M 2.61M 114M 1.32M 1.14M 1.05M 981K 1.84M 125M 1.87M 12.37M 4.82M 60.91M 4.94M 4.84M 211M
Logo OpGen Inc
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Employees
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!